TARIS Biomedical scores $32 mln

By Iris Dorbian — 4 months ago

TARIS Biomedical, which focuses on developing new treatments for urologic diseases, has secured $32 million in funding. Flagship Ventures led the round with participation from Polaris Venture Partners and RA Capital Management. Also, TARIS has appointed Dr. Christopher Cutie as vice president of clinical development. And, the company has named Kevin Finney, most recently Allergan’s vice president and corporate development head, and Mark Iwicki, most recently president and CEO of Civitas Therapeutics, to its board of directors.

Continue

Calhoun Vision nets $69 mln

By Iris Dorbian — 8 months ago

Calhoun Vision Inc, a provider of adjustable intraocular lens technology, has raised $69 million in funding. Longitude Capital led the round with participation from H.I.G. BioVentures, Balance Point Capital Partners and RA Capital Management.

Continue

Dimension Therapeutics nets $65 mln Series B

By Iris Dorbian — 10 months ago

Cambridge, Massachusetts-based Dimension Therapeutics Inc, which is focused on developing treatments for liver disorders, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, Tourbillon Global Ventures, Fidelity Biosciences and OrbiMed. In addition to the funding, Dr. Mike Dybbs, a partner at New Leaf Venture Partners, has been added to Dimension’s board of directors.

Continue

Aeglea Biotherapeutics snags $44 mln Series B

By Iris Dorbian — 11 months ago

Aeglea Biotherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has raised $44 million in Series B funding. Return backers Lilly Ventures and Novartis Venture Fund led the round with participation from other investors that included UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.

Continue

Foresite Capital leads Series B round for Allergen Research Corp

By Iris Dorbian — 11 months ago

San Mateo, California-based Allergen Research Corp, which develops treatments for food allergies, has closed $80 million in Series B funding. Foresite Capital led the round with participation from Longitude Capital, Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors. In conjunction with the funding, Dr. Jim Tananbaum, CEO and managing director of Foresite Capital and Stacey Seltzer, a partner at Aisling Capital, have been added to ARC’s board of directors.

Continue

Collegium Pharmaceutical grabs $50 mln

By Iris Dorbian — 11 months ago

Canton, Massachusetts-based Collegium Pharmaceutical Inc, a specialty pharmaceutical company focused on treating chronic pain, has secured $50 million in funding. TPG Biotech led the round with participation from RA Capital Management, Adage Capital Management, Rock Springs Capital, EcoR1 Capital, Eventide Asset Management, Aperture Venture Partners, Longitude Capital, Skyline Ventures, Frazier Healthcare and Boston Millennia Partners. In conjunction with this financing, Dr. Eran Nadav, a partner and managing director at TPG Biotech, has been added to Collegium’s board of directors.

Continue

WaVE Lifes Sciences pulls in $18 mln

By Iris Dorbian — 1 year ago

Boston and Japan-based WaVe Life Sciences, a provider of nucleic acid therapeutics, has raised $18 million in Series A funding. RA Capital Management LLC and Kagoshima Shinsangyo Sosei Investment LP led the round with participation from founding investor SNBL Ltd. In addition to the financing, Dr. Peter Kolchinsky, a managing general partner of RA Capital, has been added to WaVe’s board of directors.

Continue

VC-backed Ascendis Pharma goes public

By Iris Dorbian — 1 year ago

Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “ASND.” BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma’s backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.

Continue

Cortendo to raise up to $27.5 mln in private placement

By Iris Dorbian — 1 year ago

Cortendo AB has agreed to receive up to $27.5 million in a private placement. The investors are RA Capital Management, New Enterprise Associates, Broadfin Capital and HealthCap. Headquartered in Göteborg, Sweden and with offices in Radnor, Pennsylvania, Cortendo is a biopharmaceutical firm focused on orphan endocrine disorders.

Continue

Moderna Therapeutics scores $450 mln

By Iris Dorbian — 1 year ago

Cambridge Mass.-based biotech firm Moderna Therapeutics has closed $450 million in funding. The backers in this round include Viking Global Investors, Invus, RA Capital Management, Wellington Management Company, AstraZeneca and Alexion Pharmaceuticals.

Continue

Sofinnova Ventures, OrbiMed, Vivo Capital lead $60 mln funding in Ascendis Pharma

By Chris Witkowsky — 1 year ago

Sofinnova Ventures, OrbiMed and Vivo Capital have led a $60 million Series D funding in Ascendis Pharma, a biotechnology company. Other investors in the funding include Janus Capital Management, Venrock, RA Capital Management, Rock Springs Capital and Sectoral Asset Management. Ascendis Pharma’s largest shareholder, Sofinnova Partners, also participated in the funding round. James Healy of Sofinnova Ventures, Jonathan Silverstein of OrbiMed and Albert Cha of Vivo Capital have joined the company’s board of directors.

Continue

ZipLine Medical nabs $5.7 mln Series C

By Iris Dorbian — 1 year ago

ZipLine Medical has raised $5.7 million in Series C financing. China Materialia led the round with participation from return backers RA Capital Management, Claremont Creek Ventures and XSeed Capital. According to the firm, the capital will be used to expand its sales and marketing efforts. In addition to the funding, Dr. Min Zhou, CEO of China Materialia, has been added to ZipLine’s board of directors. Based in Campbell, Calif., ZipLine Medical is a medical device company.

Continue

Coherus BioSciences nabs $55 mln Series C

By Iris Dorbian — 2 years ago

Coherus BioSciences has raised $55 million in Series C funding. The investors included KKR, Venrock, RA Capital Management, Rock Springs Capital, Fidelity Biosciences, Sofinnova Ventures, Lilly Ventures and Vivo Capital. Based in Redwood City, Calif., Coherus BioSciences is a biologics platform focused on biosimilars.

Continue

Shire acquires VC-backed Lumena Pharmaceuticals

By Iris Dorbian — 2 years ago

Shire has acquired Lumena Pharmaceuticals. No financial terms were disclosed. Citi provided financial advice to Lumena. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders. Its backers include New Enterprise Associates, Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners.

Continue

ProNAi Therapeutics raises Series D

By Angela Sormani — 2 years ago

ProNAi Therapeutics, a developer of novel nucleic acid therapeutics has closed an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital and included other new investors Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

Continue

Lumena attracts $45 mln in Series B funds

By Iris Dorbian — 2 years ago

Lumena Pharmaceuticals said Tuesday that it has closed $45 million in Series B financing. New Enterprise Associates led the round with participation from Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders.

Continue